Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis
about
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin AmyloidosisTherapeutic Oligonucleotides Targeting Liver Disease: TTR AmyloidosisNatural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugsFirst European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathyEvolving landscape in the management of transthyretin amyloidosisTransthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic AreaTransthyretin Cardiac Amyloidosis in Older Americans.Guideline of transthyretin-related hereditary amyloidosis for clinicians.An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis.Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction.Modulating inhibitors of transthyretin fibrillogenesis via sulfation: polychlorinated biphenyl sulfates as models.In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography.Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosisThe effect of tafamidis on the QTc interval in healthy subjects.Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history studyEvaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like Cells.A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis.Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study.Tafamidis: a review of its use in familial amyloid polyneuropathy.Pathophysiology and treatment of cardiac amyloidosis.Current and future treatment of amyloid neuropathies.Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.Emerging Advances in the Management of Cardiac Amyloidosis.Drugs for the treatment of peripheral neuropathies.Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years.Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies.Current and Future Treatment Approaches in Transthyretin Familial Amyloid Polyneuropathy.Systemic amyloidosis: novel therapies and role of biomarkers.Recent Advances in Cardiovascular Imaging Relevant to the Management of Patients with Suspected Cardiac Amyloidosis.Newer Therapies for Amyloid Cardiomyopathy.One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition.Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans.Molecular interactions of amyloid nanofibrils with biological aggregation modifiers: implications for cytotoxicity mechanisms and biomaterial design.Therapeutic Strategies Targeting Inherited Cardiomyopathies.Cardiac Amyloidosis and its New Clinical Phenotype: Heart Failure with Preserved Ejection Fraction.Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy.Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).Understanding the Disease Course and Therapeutic Benefit of Tafamidis Across Real-World Studies of Hereditary Transthyretin Amyloidosis with Polyneuropathy: A Proof of Concept for Integrative Data Analytic Approaches.
P2860
Q26764754-66D907A1-FC50-4CD9-A41B-049EC84382BBQ26782089-54A18EC0-7C5D-4DA6-924F-9B945CACD5C7Q27009309-700837FC-E3CC-4D96-9B19-5D3FDCB4B44BQ28071522-3362BF46-2A44-49F3-ACE4-7F0B26488F6DQ28086773-08BB8B78-4AEF-4649-9DB4-C5F354FC1FA5Q29248271-2277C36F-1930-400C-B3A1-54326C4D9D0FQ30244227-134CD4D6-E186-414D-98B6-A9D72B8A5D70Q34328734-5AFDC9BA-50B6-42AC-9CBB-197A936D4DD4Q34428314-D545F782-9396-41BE-AD39-38C86FFE7C1EQ34838524-18096DB4-5E31-4E38-99AE-089376B416A7Q35082885-0008F2C7-61DF-48B3-AA41-F19A34F37EEDQ35119383-B3CDF317-B4DD-4A0D-8C30-051405DC2931Q35244195-6CAD380E-ECDB-4C02-932B-D3FCDAD42FE9Q35684808-A0AA1A49-A71B-4D40-A28C-92FD6AB0A5A4Q36005668-2280AE85-ABC9-47E5-A16F-E8F14D29237EQ36120100-63234D71-60FF-4324-95C2-739EF64C7BDBQ36389712-B374BED3-B7D5-4264-9B7D-98FC5B725920Q36479487-58ACB4DA-21D2-4BD2-8731-F9830EEDDCE8Q38229307-7A983523-8236-4675-AF26-A567BD82293DQ38259728-EBCD3C88-C73A-4109-9EDB-6DC2CB225D78Q38270497-95E9C850-BC0A-4444-93AC-669473D553D0Q38325612-16D42912-8A62-4CDE-854C-4475734F5748Q38587648-42A48740-9295-4392-ADF1-F79E0E360517Q38633190-DA449CB1-6E33-472B-9A62-58D1BFC6F4F4Q38652127-539D5FBA-0CE0-4B78-9680-A1D9B595A96FQ38663987-8C12DC4E-48C5-4FC5-BF97-84D60F70EAD4Q38708201-D96177C5-C04D-47F0-A5CA-2ACD1BF5A721Q38792184-7814CCFC-4E04-46EC-8BD3-D9F2E20BC203Q38829923-D9B3251D-D181-4674-AD53-3904B1D838A4Q38869625-AB3B660B-3307-4581-8024-F9E389FE58CAQ38920614-6830A86C-75AB-46F6-8416-B5DBC14E91B8Q39091511-D826A13D-EEA0-4231-849B-3B61BE61A94BQ39095033-204C3335-9955-43E7-AD72-3356A7D869A9Q39384630-17955CF0-1B13-49F2-9DB1-FC692E28BF21Q39404059-F523604E-DCDA-42C0-AC07-8C5019A813DAQ41106725-15F85CAB-0952-4916-920D-EE6AF0AC5BCCQ50113523-C7AAF652-460C-4306-9EC7-3E0AED0ABE03Q51050465-D4984DB6-1D6F-4506-A05C-95605ECD9F1DQ52597244-084D469D-0461-4811-9349-29AF00429F2FQ55215108-FFA36217-8F65-4F4F-BDCD-29CA93BC5D48
P2860
Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effects of tafamidis on transt ...... 0Met transthyretin amyloidosis
@en
Effects of tafamidis on transt ...... Met transthyretin amyloidosis.
@nl
type
label
Effects of tafamidis on transt ...... 0Met transthyretin amyloidosis
@en
Effects of tafamidis on transt ...... Met transthyretin amyloidosis.
@nl
prefLabel
Effects of tafamidis on transt ...... 0Met transthyretin amyloidosis
@en
Effects of tafamidis on transt ...... Met transthyretin amyloidosis.
@nl
P2093
P2860
P50
P921
P1476
Effects of tafamidis on transt ...... 0Met transthyretin amyloidosis
@en
P2093
Daniel P Judge
Donna R Grogan
Hartmut Schmidt
Jeff Packman
Tara Tripp
P2860
P2888
P304
P356
10.1007/S12265-013-9512-X
P407
P577
2013-10-08T00:00:00Z